| COMPOSITION | |
|---|---|
| Pantoprazole | 40MG |
| Domperidone | 10MG |
Pantoprazole Domperidone
PANTAVIB D
| SPECIFICATION | |
|---|---|
| FORM | TABLET |
| PACKING | 10×10 |
| PACKING TYPE | ALU ALU |
| MRP | 870 |
DESCRIPTION
Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem]
SIDE EFFECTS
Single intravenous doses of pantoprazole at 378, 230, and 266 mg/kg (38, 46, and 177 times the recommended human dose based on body surface area) were lethal to mice, rats and dogs, respectively. The symptoms of toxicity included hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor. There is limited experience regarding cases of human overdosage, and treatment should be symptomatic and supportive.
Side effects include galactorrhea, gynecomastia, or menstrual irregularities.
INDICATION
Short-term (up to 16 weeks) treatment of erosive esophagitis.
For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.